Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that SciClone Pharmaceuticals (Holdings) Limited (“SciClone Pharmaceuticals”) has submitted the Biologics License Application (“BLA”) for DANYELZA® (naxitamab-gqgk) for the treatment of patients with relapsed/refractory high-risk neuroblastoma to the National Medical Products Administration (“NMPA”) of China.

The rest is here:
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China

Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del., July 06, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, July 13, 2021 at 9:00 am ET.

Go here to read the rest:
Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

Praxis Precision Medicines to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:

See the article here:
Praxis Precision Medicines to Present at Upcoming Investor Conferences

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND targeted for the end of 2022.

Read more here:
Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum

NEW YORK, NY, July 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York-based diversified Life Sciences Company, today announced that its Brand Registry Application for its flagship Tauri-Gum™ brand has been approved by Amazon Inc. (“Amazon”).  Amazon Brand Registry helps the Company protect its registered Trademarks and create a trusted experience for customers. Additionally, Amazon provides a suite of tools that enable rich text images on the Amazon detail page – which helps a business drive customer conversion and increased traffic & sales.

See the original post:
Amazon Brand Registry Approves the Application for the Company’s Flagship Brand: Tauri-Gum

Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

Saint-Herblain (France), July 6, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations.

Original post:
Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company’s board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital markets and strategic expertise, and prior board level experience.

Originally posted here:
CoImmune, Inc. Appoints Michael Fekete and Greg Tibbitts to its Board of Directors

ZEALAND PHARMA A/S – TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

Company announcement – No. 45/ 2021

Read the original here:
ZEALAND PHARMA A/S - TRANSACTIONS UNDER SHARE REPURCHASE PROGRAM

Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021

Visit link:
Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2021

Integrity Implants and Fusion Robotics Merge to Form Accelus

Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine Accelus to Offer Procedure-Enabling Technology with the Goal of Making Minimally Invasive Surgery (MIS) the Standard of Care in Spine

Read more from the original source:
Integrity Implants and Fusion Robotics Merge to Form Accelus